The historical rank and industry rank for Tissue Regenix Group's Gross Margin % or its related term are showing as below:
FRA:LSW'
s Gross Margin % Range Over the Past 10 Years
Min: 40.94 Med: 48.44 Max: 81.21
Current: 40.94
During the past 13 years, the highestGross Margin % of Tissue Regenix Group was 81.21%. The lowest was 40.94%. And the median was 48.44%.
FRA:LSW's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 60.92
vs FRA:LSW: 40.94
Tissue Regenix Group had a gross margin of 41.83% for the quarter that ended in Jun. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Tissue Regenix Group was 1.20% per year.
Tissue Regenix Group (FRA:LSW) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Tissue Regenix Group had a gross margin of 41.83% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Tissue Regenix Group Gross Margin % Related Terms
Tissue Regenix Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Tissue Regenix Group (FRA:LSW) has a Gross Margin % of 41.83% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Tissue Regenix Group and its competitors. This is 14% below median its historical median of 48.44. Over the past decade, Tissue Regenix Group's Gross Margin % has ranged from 40.94 to 81.21.
Is Tissue Regenix Group's Gross Margin % too high?
Tissue Regenix Group's current Gross Margin % of 41.83% is 14% below median its 10-year median of 48.44. Over the past 10 years, this metric has ranged from a low of 40.94 to a high of 81.21. The Biotechnology industry median Gross Margin % is 60.92. Tissue Regenix Group's value of 41.83% is 31.3% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Gross Margin % compare to VRTX and REGN?
Tissue Regenix Group's Gross Margin % of 41.83% can be compared against companies in the Biotechnology industry. The industry median Gross Margin % is 60.92. Tissue Regenix Group's value of 41.83% is 31.3% below this benchmark. Historically, Tissue Regenix Group's own Gross Margin % has ranged from 40.94 to 81.21 over the past decade. While the company's 10-year median is 48.44 vs. the industry median of 60.92, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Gross Margin % of 41.83% is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Gross Margin % is 41.83%, which is 14% below median its own 10-year median of 48.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Gross Margin % of 41.83%. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Gross Margin % is 41.83%, which is 14% below median its 10-year median of 48.44 and 31.3% below the Biotechnology industry median of 60.92. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Gross Margin % is 41.83% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Gross Margin %: 41.83% (14% below median its 10-year median of 48.44)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 31.3% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
